Seres Stock Analysis

MCRB
 Stock
  

USD 6.36  0.14  2.15%   

The current price rise of Seres Therapeutics may encourage investors to take a closer look at the company as it is trading at a share price of 6.36 on 111,237 in trading volume. The company executives may have good odds in positioning the company resources to exploit market volatility in January. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.13. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Seres Therapeutics partners.
Additionally, see Correlation Analysis.
  
The Seres Therapeutics stock analysis report makes it easy to digest most publicly released information about Seres Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Seres Stock analysis module also helps to analyze the Seres Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Seres Stock Analysis Notes

About 86.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.94. Seres Therapeutics had not issued any dividends in recent years. Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Seres Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 333 people. To find out more about Seres Therapeutics contact Roger Pomerantz at 617 945 9626 or learn more at https://www.serestherapeutics.com.

Seres Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Seres Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Seres Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Seres Therapeutics has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 144.93 M. Net Loss for the year was (65.58 M) with profit before overhead, payroll, taxes, and interest of 3.04 M.
Over 86.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: U.S. FDA gives first-ever approval to fecal transplant therapy - Marketscreener.com

Seres Therapeutics Upcoming and Recent Events

Earnings reports are used by Seres Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Seres Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report1st of March 2022
Next Financial Report3rd of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End1st of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Seres Largest EPS Surprises

Earnings surprises can significantly impact Seres Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-03-02
2019-12-31-0.28-0.250.0310 
2021-03-02
2020-12-31-0.28-0.230.0517 
2015-11-10
2015-09-30-0.32-0.38-0.0618 
View All Earnings Estimates

Seres Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Seres Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Seres Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Seres Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
9th of August 2022
Unclassified Corporate Event
View
3rd of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
22nd of July 2022
Unclassified Corporate Event
View
11th of July 2022
Unclassified Corporate Event
View
7th of July 2022
Unclassified Corporate Event
View
30th of June 2022
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
24th of June 2022
Submission of Matters to a Vote of Security Holders
View
7th of June 2022
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
View

Seres Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 844.73 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Seres Therapeutics's market, we take the total number of its shares issued and multiply it by Seres Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Seres Profitablity

Seres Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Seres Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Seres Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Seres Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Seres Therapeutics' profitability requires more research than a typical breakdown of Seres Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(36.23) (39.09) 
Return on Average Assets(18.80) (20.28) 
Return on Average Equity(42.83) (46.21) 
Return on Invested Capital(0.38) (0.40) 
Return on Sales(0.43) (0.46) 

Management Efficiency

The entity has return on total asset (ROA) of (0.4018) % which means that it has lost $0.4018 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (1.9017) %, meaning that it created substantial loss on money invested by shareholders. Seres Therapeutics management efficiency ratios could be used to measure how well seres therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2022, Return on Investment is expected to decline to -39.09. In addition to that, Return on Average Assets is expected to decline to -20.28. Seres Therapeutics Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 354.86 Million. The current year Current Assets is expected to grow to about 327.6 M, whereas Assets Non Current are forecasted to decline to about 46.7 M.
Last ReportedProjected for 2022
Book Value per Share 1.43  1.37 
Enterprise Value over EBIT(9.00) (9.71) 
Enterprise Value over EBITDA(10.88) (11.74) 
Price to Book Value 5.82  5.24 
Tangible Assets Book Value per Share 3.87  4.47 
Enterprise Value581.4 M719.4 M
Tangible Asset Value354.9 M299.3 M

Technical Drivers

As of the 1st of December, Seres Therapeutics has the Semi Deviation of 4.61, risk adjusted performance of 0.1353, and Coefficient Of Variation of 1165.05. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Seres Therapeutics, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Seres Therapeutics, which can be compared to its competition. Please validate Seres Therapeutics treynor ratio, as well as the relationship between the potential upside and expected short fall to decide if Seres Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 6.36 per share. Given that Seres Therapeutics has jensen alpha of 0.427, we advise you to double-check Seres Therapeutics's current market performance to make sure the company can sustain itself at a future point.

Seres Therapeutics Price Movement Analysis

The output start index for this execution was three with a total number of output elements of fifty-eight. Seres Therapeutics Triple Exponential Moving Average indicator shows smoothing effect of Seres Therapeutics price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
.

Seres Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Seres Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Seres Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Seres Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Seres Therapeutics Predictive Daily Indicators

Seres Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Seres Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Seres Therapeutics Forecast Models

Seres Therapeutics time-series forecasting models is one of many Seres Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Seres Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Seres Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Seres Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Seres shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Seres Therapeutics. By using and applying Seres Stock analysis, traders can create a robust methodology for identifying Seres entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(40.05) (43.21) 
EBITDA Margin(37.01) (39.93) 
Gross Margin 0.90  0.89 
Profit Margin(40.72) (43.94) 

Current Seres Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Seres analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Seres analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
22.83Strong Buy6Odds
Seres Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Seres analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Seres stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Seres Therapeutics, talking to its executives and customers, or listening to Seres conference calls.
Seres Analyst Advice Details

Seres Stock Analysis Indicators

Seres Therapeutics stock analysis indicators help investors evaluate how Seres Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Seres Therapeutics shares will generate the highest return on investment. By understating and applying Seres Therapeutics stock analysis, traders can identify Seres Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow116049000.00
Logo U R LimglogosUSMCRB.png
Common Stock Shares Outstanding79789220.00
Total Stockholder Equity131507000.00
Total Cashflows From Investing Activities64088000.00
Property Plant And Equipment Net36146000.00
Retained Earnings-614354000.00
Cash And Short Term Investments290706000.00
Retained Earnings Total Equity-614354000.00
Cash180002000.00
CodeMCRB
Accounts Payable13735000.00
Net Debt-130866000.00
50 Day M A6.915
Total Current Liabilities82258000.00
Currency CodeUSD
Other Operating Expenses1732000.00
Non Current Assets Total51231000.00
Common Stock Total Equity92000.00
Non Currrent Assets Other14590000.00
Additionally, see Correlation Analysis. You can also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for analysis

When running Seres Therapeutics price analysis, check to measure Seres Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seres Therapeutics is operating at the current time. Most of Seres Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seres Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Seres Therapeutics' price. Additionally, you may evaluate how the addition of Seres Therapeutics to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Is Seres Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
844.7 M
Quarterly Revenue Growth YOY
(0.97) 
Return On Assets
(0.40) 
Return On Equity
(1.90) 
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Seres Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.